Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
COMPENSATION 2026
ABOUT
UPCOMING EARNINGS
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-12-06 | Reverse | 1:15 |
| 2023-03-31 | Reverse | 1:12 |
| 2022-10-28 | Reverse | 1:20 |
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$0.53 ▲ UP 15.07% (+$0.07)About Ensysce Biosciences, Inc.
https://www.ensysce.com ↗Ensysce Biosciences is a clinical-stage biotech developing abuse-resistant and overdose-protective opioid prodrugs, including PF614 and PF26810, for pain management, addiction, and overdose prevention.
INDUSTRY
A PRODUCT ENSYSCE BIOSCIENCES, INC. IS KNOWN FOR
PF614, a clinical-stage opioid from Ensysce's TAAP platform, is designed to treat severe pain with abuse prevention features and is currently in Phase 3 trials assessing its safety and efficacy.
Ensysce Biosciences in 2025
Ensysce Biosciences Receives Positive FDA Feedback, Clearing Path for Commercial Manufacturing of Lead Opioid Candidate PF614
In November 2025, Ensysce Biosciences announced it had received positive written feedback from the U.S. Food and Drug Administration (FDA) that aligned with the company's proposed commercial manufacturing strategy for its lead drug candidate, PF614. This event was highly notable as it significantly de-risked the company's path to market by validating its manufacturing, chemistry, and controls (CMC) approach, a critical step required for a New Drug Application (NDA) submission.
Ensysce Biosciences Initiates Pivotal Phase 3 Trial for Next-Generation Opioid PF614, Advancing Towards Market Launch
Ensysce Biosciences achieved a major milestone by initiating enrollment in its pivotal Phase 3 clinical trial for PF614, its lead next-generation, abuse-deterrent opioid. This final stage of clinical development is designed to validate PF614's effectiveness in managing severe pain and is a critical step toward a potential New Drug Application and commercialization.
RATINGS SNAPSHOT
Overall rating: C+
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 KZIA | $9.06 | COMPARE |
 KALA | $0.29 | COMPARE |
 SNGX | $0.35 | COMPARE |
 XBIO | $2.12 | COMPARE |